Research ExplorerPublicationsMatched comparison of next- and early-generation balloon-exp...

Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses

Standard

Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses. / Seiffert, Moritz; Treede, Hendrik; Schofer, Joachim; Linke, Axel; Woehrle, Jochen; Baumbach, Hardy; Mehilli, Julinda; Bapat, Vinayak; Simonato, Matheus; Walther, Thomas; Kullmer, Mathias; Boekstegers, Peter; Ensminger, Stephan; Kurz, Thomas; Eltchaninoff, Hélène; Rastan, Ardawan; Werner, Nicolas; de Weger, Arend; Frerker, Christian; Lauer, Bernward; Muller, Olivier; Whisenant, Brian; Thukkani, Arun; Weisz, Giora; Dvir, Danny.

In: EUROINTERVENTION, Vol. 14, No. 4, 20.07.2018, p. e397-e404.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Seiffert, M, Treede, H, Schofer, J, Linke, A, Woehrle, J, Baumbach, H, Mehilli, J, Bapat, V, Simonato, M, Walther, T, Kullmer, M, Boekstegers, P, Ensminger, S, Kurz, T, Eltchaninoff, H, Rastan, A, Werner, N, de Weger, A, Frerker, C, Lauer, B, Muller, O, Whisenant, B, Thukkani, A, Weisz, G & Dvir, D 2018, 'Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses', EUROINTERVENTION, vol. 14, no. 4, pp. e397-e404. https://doi.org/10.4244/EIJ-D-17-00546

APA

Seiffert, M., Treede, H., Schofer, J., Linke, A., Woehrle, J., Baumbach, H., Mehilli, J., Bapat, V., Simonato, M., Walther, T., Kullmer, M., Boekstegers, P., Ensminger, S., Kurz, T., Eltchaninoff, H., Rastan, A., Werner, N., de Weger, A., Frerker, C., ... Dvir, D. (2018). Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses. EUROINTERVENTION, 14(4), e397-e404. https://doi.org/10.4244/EIJ-D-17-00546

Vancouver

Seiffert M, Treede H, Schofer J, Linke A, Woehrle J, Baumbach H et al. Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses. EUROINTERVENTION. 2018 Jul 20;14(4):e397-e404. https://doi.org/10.4244/EIJ-D-17-00546

Bibtex

@article{cc8c8b6d9d1344fe8e0da46312215ba0,
title = "Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses",
abstract = "AIMS: Transcatheter valve-in-valve implantation (VinV) is established for the treatment of degenerated surgical bioprostheses in patients at high operative risk. Our aim was to report on the first large assessment of VinV with next-generation balloon-expandable transcatheter heart valves.METHODS AND RESULTS: After SAPIEN XT or SAPIEN 3 VinV, 514 patients were analysed using an inverse probability of treatment weighting. Standardised clinical and haemodynamic outcomes were compared, and core laboratory evaluation of implantation depth was performed. Thirty-day all-cause mortality was 0.6% and 3.5% for SAPIEN 3 and SAPIEN XT (p=0.077). Residual transprosthetic gradient ≥20 mmHg was observed in 38.3% (SAPIEN 3) and 35.7% (SAPIEN XT) of patients (p=0.627) with increased rates in small bioprostheses (≤21 mm true ID). In SAPIEN 3 VinV, low implantation depth >20% THV stent frame length was associated with a higher rate of elevated transaortic gradients (p=0.048). Similarly, an implantation depth >5 mm was linked to more pacemaker implantations (p=0.01). Overall, a trend towards higher pacemaker implantation rates was observed after SAPIEN 3 VinV (6% vs. 2.5% in SAPIEN XT, p=0.071).CONCLUSIONS: Transcatheter aortic VinV with the balloon-expandable SAPIEN XT or SAPIEN 3 was similarly safe and effective. However, residual stenosis remains a concern, particularly in smaller bioprostheses and with increasing implantation depth.",
keywords = "Aortic Valve, Aortic Valve Stenosis, Bioprosthesis, Heart Valve Prosthesis, Humans, Prosthesis Design, Transcatheter Aortic Valve Replacement, Treatment Outcome",
author = "Moritz Seiffert and Hendrik Treede and Joachim Schofer and Axel Linke and Jochen Woehrle and Hardy Baumbach and Julinda Mehilli and Vinayak Bapat and Matheus Simonato and Thomas Walther and Mathias Kullmer and Peter Boekstegers and Stephan Ensminger and Thomas Kurz and H{\'e}l{\`e}ne Eltchaninoff and Ardawan Rastan and Nicolas Werner and {de Weger}, Arend and Christian Frerker and Bernward Lauer and Olivier Muller and Brian Whisenant and Arun Thukkani and Giora Weisz and Danny Dvir",
year = "2018",
month = jul,
day = "20",
doi = "10.4244/EIJ-D-17-00546",
language = "English",
volume = "14",
pages = "e397--e404",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "4",

}

RIS

TY - JOUR

T1 - Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses

AU - Seiffert, Moritz

AU - Treede, Hendrik

AU - Schofer, Joachim

AU - Linke, Axel

AU - Woehrle, Jochen

AU - Baumbach, Hardy

AU - Mehilli, Julinda

AU - Bapat, Vinayak

AU - Simonato, Matheus

AU - Walther, Thomas

AU - Kullmer, Mathias

AU - Boekstegers, Peter

AU - Ensminger, Stephan

AU - Kurz, Thomas

AU - Eltchaninoff, Hélène

AU - Rastan, Ardawan

AU - Werner, Nicolas

AU - de Weger, Arend

AU - Frerker, Christian

AU - Lauer, Bernward

AU - Muller, Olivier

AU - Whisenant, Brian

AU - Thukkani, Arun

AU - Weisz, Giora

AU - Dvir, Danny

PY - 2018/7/20

Y1 - 2018/7/20

N2 - AIMS: Transcatheter valve-in-valve implantation (VinV) is established for the treatment of degenerated surgical bioprostheses in patients at high operative risk. Our aim was to report on the first large assessment of VinV with next-generation balloon-expandable transcatheter heart valves.METHODS AND RESULTS: After SAPIEN XT or SAPIEN 3 VinV, 514 patients were analysed using an inverse probability of treatment weighting. Standardised clinical and haemodynamic outcomes were compared, and core laboratory evaluation of implantation depth was performed. Thirty-day all-cause mortality was 0.6% and 3.5% for SAPIEN 3 and SAPIEN XT (p=0.077). Residual transprosthetic gradient ≥20 mmHg was observed in 38.3% (SAPIEN 3) and 35.7% (SAPIEN XT) of patients (p=0.627) with increased rates in small bioprostheses (≤21 mm true ID). In SAPIEN 3 VinV, low implantation depth >20% THV stent frame length was associated with a higher rate of elevated transaortic gradients (p=0.048). Similarly, an implantation depth >5 mm was linked to more pacemaker implantations (p=0.01). Overall, a trend towards higher pacemaker implantation rates was observed after SAPIEN 3 VinV (6% vs. 2.5% in SAPIEN XT, p=0.071).CONCLUSIONS: Transcatheter aortic VinV with the balloon-expandable SAPIEN XT or SAPIEN 3 was similarly safe and effective. However, residual stenosis remains a concern, particularly in smaller bioprostheses and with increasing implantation depth.

AB - AIMS: Transcatheter valve-in-valve implantation (VinV) is established for the treatment of degenerated surgical bioprostheses in patients at high operative risk. Our aim was to report on the first large assessment of VinV with next-generation balloon-expandable transcatheter heart valves.METHODS AND RESULTS: After SAPIEN XT or SAPIEN 3 VinV, 514 patients were analysed using an inverse probability of treatment weighting. Standardised clinical and haemodynamic outcomes were compared, and core laboratory evaluation of implantation depth was performed. Thirty-day all-cause mortality was 0.6% and 3.5% for SAPIEN 3 and SAPIEN XT (p=0.077). Residual transprosthetic gradient ≥20 mmHg was observed in 38.3% (SAPIEN 3) and 35.7% (SAPIEN XT) of patients (p=0.627) with increased rates in small bioprostheses (≤21 mm true ID). In SAPIEN 3 VinV, low implantation depth >20% THV stent frame length was associated with a higher rate of elevated transaortic gradients (p=0.048). Similarly, an implantation depth >5 mm was linked to more pacemaker implantations (p=0.01). Overall, a trend towards higher pacemaker implantation rates was observed after SAPIEN 3 VinV (6% vs. 2.5% in SAPIEN XT, p=0.071).CONCLUSIONS: Transcatheter aortic VinV with the balloon-expandable SAPIEN XT or SAPIEN 3 was similarly safe and effective. However, residual stenosis remains a concern, particularly in smaller bioprostheses and with increasing implantation depth.

KW - Aortic Valve

KW - Aortic Valve Stenosis

KW - Bioprosthesis

KW - Heart Valve Prosthesis

KW - Humans

KW - Prosthesis Design

KW - Transcatheter Aortic Valve Replacement

KW - Treatment Outcome

U2 - 10.4244/EIJ-D-17-00546

DO - 10.4244/EIJ-D-17-00546

M3 - SCORING: Journal article

C2 - 29688174

VL - 14

SP - e397-e404

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 4

ER -